Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial.

Background: There is increasing evidence for the use of exercise in cancer patients and data supporting enhanced tumour volume reduction following chemotherapy in animal models. To date, there is no reported histopathological evidence of a similar oncological benefit in oesophageal cancer.

Methods: A prospective non-randomised trial compared a structured prehabilitation exercise intervention during neoadjuvant chemotherapy and surgery versus conventional best-practice for oesophageal cancer patients.

The Antibody Two-Step Solution.

Problems with antibody quality have been described in numerous recent publications.  In the present commentary it is argued that these quality problems are due primarily to issues of antibody variability and antibody validation.  Further it is argued that the problem of antibody variability must be solved before validation can be useful.